DrugPatentWatch Database Preview
Drugs in Development Information for Asunaprevir
» See Plans and Pricing
What is the development status for investigational drug Asunaprevir?
Asunaprevir is an investigational drug.
There have been 38 clinical trials for Asunaprevir.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis A. The leading clinical trial sponsors are Bristol-Myers Squibb, French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS), and Kirby Institute.
There are twenty-nine US patents protecting this investigational drug and three hundred and thirty-nine international patents.
Summary for Asunaprevir
| US Patents | 29 |
| International Patents | 339 |
| US Patent Applications | 43 |
| WIPO Patent Applications | 487 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2015-12-01) |
| Vendors | 41 |
Recent Clinical Trials for Asunaprevir
| Title | Sponsor | Phase |
|---|---|---|
| Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir | Kirby Institute | Phase 4 |
| Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection | Humanity & Health Medical Group Limited | Phase 2 |
| Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV | Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 3 |
Clinical Trial Summary for Asunaprevir
Top disease conditions for Asunaprevir
Top clinical trial sponsors for Asunaprevir
US Patents for Asunaprevir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Asunaprevir | Start Trial | Method for treating HCV | AbbVie Inc. (North Chicago, IL) | Start Trial |
| Asunaprevir | Start Trial | Hepatitis C virus inhibitors | Bristol-Myers Squibb Company (Princeton, NJ) | Start Trial |
| Asunaprevir | Start Trial | Hepatitis C virus inhibitors | Bristol-Myers Squibb Company (Princeton, NJ) | Start Trial |
| Asunaprevir | Start Trial | Hepatitis C virus inhibitors | Bristol-Myers Squibb Company (Princeton, NJ) | Start Trial |
| Asunaprevir | Start Trial | Hepatitis C virus inhibitors | Bristol-Myers Squibb Company (Princeton, NJ) | Start Trial |
| Asunaprevir | Start Trial | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-is- oquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolina- mide | Bristol-Myers Squibb Company (Princeton, NJ) | Start Trial |
| Asunaprevir | Start Trial | Hepatitis C virus inhibitors | Bristol-Myers Squibb Company (Princeton, NJ) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Asunaprevir
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Asunaprevir | Australia | AU2014239563 | 2033-03-14 | Start Trial |
| Asunaprevir | Australia | AU2015240754 | 2033-03-14 | Start Trial |
| Asunaprevir | Australia | AU2016202823 | 2033-03-14 | Start Trial |
| Asunaprevir | Australia | AU2016291154 | 2033-03-14 | Start Trial |
| Asunaprevir | Australia | AU2017248487 | 2033-03-14 | Start Trial |
| Asunaprevir | Australia | AU2018201011 | 2033-03-14 | Start Trial |
| Asunaprevir | Australia | AU2018311684 | 2033-03-14 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
